
Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – Investment analysts at HC Wainwright cut their FY2026 EPS estimates for Spyglass Pharma in a report issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($2.76) per share for the year, down from their previous estimate of ($2.52). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.07).
A number of other analysts also recently issued reports on the company. UBS Group reiterated a “buy” rating on shares of Spyglass Pharma in a research report on Monday, October 5th. Stifel Nicolaus upped their price objective on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Citigroup lifted their target price on shares of Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $45.83.
Get Our Latest Research Report on Spyglass Pharma
Spyglass Pharma Stock Performance
Spyglass Pharma stock opened at $32.24 on Monday. The business has a 50-day simple moving average of $28.85 and a 200 day simple moving average of $24.87. Spyglass Pharma has a 52 week low of $17.06 and a 52 week high of $39.92.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in SGP. First Light Asset Management LLC bought a new stake in Spyglass Pharma during the first quarter worth about $9,716,000. Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $6,478,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $2,461,000. Bank of America Corp DE purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $726,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Spyglass Pharma during the 2nd quarter valued at about $533,000.
Trending Headlines about Spyglass Pharma
Here are a few of the latest headlines about SGP:
- Positive Sentiment: Spyglass Pharma’s price target was raised to $44, signaling improved potential upside in the analyst’s view. Spyglass Pharma price target raised to $44
- Negative Sentiment: HC Wainwright lowered its earnings forecasts for several 2026 and 2027 periods, including FY2026 EPS to a loss of $2.76 from $2.52 and FY2027 EPS to a loss of $2.64 from $2.57. The firm nevertheless kept its Buy rating and $43 target.
- Negative Sentiment: The company’s latest quarterly loss of $0.73 per share was wider than analysts’ $0.66 estimate, adding to concerns about near-term results.
Spyglass Pharma Company Profile
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
Recommended Stories
- Five stocks we like better than Spyglass Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
